170 related articles for article (PubMed ID: 37791673)
21. The protective effects of Δ
Beydogan AB; Coskun ZM; Bolkent S
J Pharm Pharmacol; 2019 Mar; 71(3):408-416. PubMed ID: 30427077
[TBL] [Abstract][Full Text] [Related]
22. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
23. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
Hare JI; Neijzen RW; Anantha M; Dos Santos N; Harasym N; Webb MS; Allen TM; Bally MB; Waterhouse DN
PLoS One; 2013; 8(4):e62349. PubMed ID: 23626804
[TBL] [Abstract][Full Text] [Related]
24. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
25. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Zhu LX; Sharma S; Stolina M; Gardner B; Roth MD; Tashkin DP; Dubinett SM
J Immunol; 2000 Jul; 165(1):373-80. PubMed ID: 10861074
[TBL] [Abstract][Full Text] [Related]
26. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
Greenhough A; Patsos HA; Williams AC; Paraskeva C
Int J Cancer; 2007 Nov; 121(10):2172-80. PubMed ID: 17583570
[TBL] [Abstract][Full Text] [Related]
27. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
28. A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver.
Melancon MP; Yevich S; Avritscher R; Swigost A; Lu L; Tian L; Damasco JA; Dixon K; Cortes AC; Munoz NM; Liang D; Liu D; Tam AL
Drug Deliv; 2021 Dec; 28(1):240-251. PubMed ID: 33501859
[TBL] [Abstract][Full Text] [Related]
29. Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila.
Smith MS; Yamamoto Y; Newton C; Friedman H; Klein T
Proc Soc Exp Biol Med; 1997 Jan; 214(1):69-75. PubMed ID: 9012363
[TBL] [Abstract][Full Text] [Related]
30. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study.
de Vries M; van Rijckevorsel DCM; Vissers KCP; Wilder-Smith OHG; van Goor H;
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1079-1086.e4. PubMed ID: 27720917
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
[TBL] [Abstract][Full Text] [Related]
32. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
34. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
35. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Wulaningsih W; Wardhana A; Watkins J; Yoshuantari N; Repana D; Van Hemelrijck M
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008593. PubMed ID: 26869023
[TBL] [Abstract][Full Text] [Related]
36. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
37. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model.
Tran TA; Kim YH; Duong TH; Thangaraj J; Chu TH; Jung S; Kim IY; Moon KS; Kim YJ; Lee TK; Lee CW; Yun H; Lee JJ; Lee HJ; Lee KH; Jung TY
Front Immunol; 2022; 13():1009484. PubMed ID: 36703992
[TBL] [Abstract][Full Text] [Related]
39. Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
El-Salhy M; Hilding L; Royson H; Tjomsland V
Int J Oncol; 2005 Sep; 27(3):687-91. PubMed ID: 16077917
[TBL] [Abstract][Full Text] [Related]
40. Comparative Pharmacokinetics of Δ
Torrens A; Vozella V; Huff H; McNeil B; Ahmed F; Ghidini A; Mahler SV; Huestis MA; Das A; Piomelli D
J Pharmacol Exp Ther; 2020 Jul; 374(1):151-160. PubMed ID: 32345621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]